Aligos therapeutics announces reverse stock split

South san francisco, calif., aug. 15, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”, “company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. the reverse stock split will become effective at 12:01 am et on monday, august 19, 2024. the company's common stock is expected begin trading on the nasdaq capital market under the same symbol (algs) on a split-adjusted basis at the market open on august 19, 2024 with the new cusip number 01626l 204.
ALGS Ratings Summary
ALGS Quant Ranking